Morgan Stanley noted that this is “an incremental negative” for the stock. However, it maintains its ‘Overweight’ rating on the stock.
BioNTech Stock Dips On FDA Concerns Over Cancer Drug Trial: Retail Response Mixed
Stocktwits - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here